Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0DN0W
|
|||
| Drug Name |
Niraparib Tosylate
|
|||
| Synonyms |
1038915-73-9; MK-4827 (tosylate); MK-4827 tosylate; UNII-75KE12AY9U; MK-4827(Niraparib) tosylate; 75KE12AY9U; MK-4827-tosylate; MK 4827 tosylate; Niraparib(MK-4827) tosylate; KS-00000TSH; MolPort-044-556-849; s7625; HY-10619B; AKOS030632785; CS-2283; AC-30383; KB-335358; AX8326059
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Fallopian tube cancer [ICD-11: 2C74; ICD-10: C57.0] | Approved | [1] | |
| Peritoneal cancer [ICD-11: 2C51.Z] | Approved | [1], [2] | ||
| Therapeutic Class |
Antihypertensive Agents
|
|||
| Company |
Tesaro
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C26H28N4O4S
|
|||
| Canonical SMILES |
CC1=CC=C(C=C1)S(=O)(=O)O.C1CC(CNC1)C2=CC=C(C=C2)N3C=C4C=CC=C(C4=N3)C(=O)N
|
|||
| InChI |
1S/C19H20N4O.C7H8O3S/c20-19(24)17-5-1-3-15-12-23(22-18(15)17)16-8-6-13(7-9-16)14-4-2-10-21-11-14;1-6-2-4-7(5-3-6)11(8,9)10/h1,3,5-9,12,14,21H,2,4,10-11H2,(H2,20,24);2-5H,1H3,(H,8,9,10)/t14-;/m1./s1
|
|||
| InChIKey |
LCPFHXWLJMNKNC-PFEQFJNWSA-N
|
|||
| CAS Number |
CAS 1038915-73-9
|
|||
| PubChem Compound ID | ||||
| SuperDrug ATC ID |
N07BC04
|
|||
| SuperDrug CAS ID |
cas=031036803
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Poly [ADP-ribose] polymerase 1 (PARP1) | Target Info | Modulator | [3] |
| KEGG Pathway | Base excision repair | |||
| NF-kappa B signaling pathway | ||||
| Panther Pathway | FAS signaling pathway | |||
| Pathway Interaction Database | Integrin-linked kinase signaling | |||
| Caspase Cascade in Apoptosis | ||||
| Notch-mediated HES/HEY network | ||||
| Reactome | Dual Incision in GG-NER | |||
| WikiPathways | FAS pathway and Stress induction of HSP regulation | |||
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | ||||
| Nanoparticle triggered regulated necrosis | ||||
| Corticotropin-releasing hormone | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. | |||
| REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2018 | |||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.